R&D Center
PCG-BIOTECH aims to develop innovative anticancer drugs with fewer side effects.
Pipeline
Indication | Pipeline | Platform | Development Stage | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Target Validation |
Discovery (Hit to Lead) |
Lead Optimization |
PreClinical Development |
IND enabling |
PhaseⅠ | PhaseⅡ | PhaseⅢ | |||
Acute Myeloid Leukemia (AML) |
PCG-C001 (First-in-Class) |
Chemical | ![]() |
![]() |
||||||
Metastatic Triple-Negative Breast Cancer (TNBC) |
PCG-C002 (First-in-Class) |
Ab/ADC | ![]() |
|||||||
PCG-C003 (First-in-Class) |
Chemical | ![]() |
||||||||
Metastatic Colorectal Cancer (CC) |
PCG-C004 (First-in-Class) |
Ab/ADC | ![]() |
|||||||
Huntington's disease (HD) |
PCG-N001 (First-in-Class) |
Chemical | ![]() |
|||||||
Small Cell Lung Cancer (SCLC) |
PCG-C005 (First-in-Class) |
Ab/ Chemical |
![]() |
|||||||
Liver Cancer (LC) |
PCG-C006 (First-in-Class) |
Ab/ADC | ![]() |
|||||||
Bipolar Disorder (ND) |
PCG-N002 (First-in-Class) |
Chemical | ![]() |
|||||||
Degenerative Diseases (AD, PD) |
PCG-N003 (First-in-Class) |
Ab/ADC | ![]() |